Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Xenogen (XGEN) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (15)	4/12/2005 6:29:39 PM
From: tuck	Read Replies (1) \| Respond to of 45

First publication of in vivo imaging by the competitors: >>Mol Microbiol. 1995 Nov;18(4):593-603. Photonic detection of bacterial pathogens in living hosts. Contag CH, Contag PR, Mullins JI, Spilman SD, Stevenson DK, Benaron DA. Department of Microbiology and Immunology, Stanford University School of Medicine, California 94305-5402, USA. ccontag@cmgm.stanford.edu The study of pathogenic processes is often limited to ex vivo assays and cell-culture correlates. A greater understanding of infectious diseases would be facilitated by in vivo analyses. Therefore, we have developed a method for detecting bacterial pathogens in a living host and used this method to evaluate disease processes for strains of Salmonella typhimurlum that differ in their virulence for mice. Three strains of Salmonella were marked with bioluminescence through transformation with a plasmid conferring constitutive expression of bacterial luciferase. Detection of photons transmitted through tissues of animals infected with bioluminescent Salmonella allowed localization of the bacteria to specific tissues. In this manner progressive infections were distinguished from those that were persistent or abortive. We observed patterns of bioluminescence that suggested the caecum may play a pivotal role in Salmonella pathogenesis. In vivo efficacy of an antibiotic was monitored using this optical method. This study demonstrates that real time non-invasive analyses of pathogenic events and pharmacological monitoring can be performed in vivo.<< AntiCancer's: anticancer.com is from '97. However, their work in animal models goes way back into the 80s, before Contag even started. AntiCancer might have a case regarding the animal models, but not -- as far as I can tell -- the imaging or reporting methods. Betcha this can be settled for a small license fee, and Xenogen can continue to kick AntiCancer's tail wrt to selling systems. Cheers, Tuck